AZD4573 is primarily investigated for its potential in cancer therapy, particularly in targeting hematologic malignancies. It functions as a selective inhibitor of cyclin-dependent kinases (CDKs), which play a crucial role in cell cycle regulation. By inhibiting these kinases, AZD4573 aims to disrupt the proliferation of cancer cells, leading to their apoptosis. This makes it a promising candidate for treating cancers like leukemia and lymphoma, where uncontrolled cell division is a hallmark. Ongoing clinical trials are evaluating its efficacy, safety, and optimal dosing regimens in patients with advanced or refractory blood cancers.